MCID: ACT073
MIFTS: 59

Acute Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Acute Leukemia

MalaCards integrated aliases for Acute Leukemia:

Name: Acute Leukemia 12 29 54 15 37 17 70
Acute Undifferentiated Leukemia 70
Undifferentiated Leukemia 70
Stem Cell Leukaemia 12
Stem Cell Leukemia 12
Acute Leukemias 15

Classifications:



External Ids:

Disease Ontology 12 DOID:12603
ICD9CM 34 208.0
NCIt 50 C9300
SNOMED-CT 67 24072005
ICD10 32 C95.00
UMLS 70 C0085669 C0280141 C1378511

Summaries for Acute Leukemia

Disease Ontology : 12 A lymphoid leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity producing large numbers of white blood cells to be produced and enter the blood stream.

MalaCards based summary : Acute Leukemia, also known as acute undifferentiated leukemia, is related to mixed phenotype acute leukemia and leukemia, acute myeloid. An important gene associated with Acute Leukemia is WT1 (WT1 Transcription Factor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Aldosterone synthesis and secretion. The drugs Cefepime and Ceftazidime have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original... more...

Related Diseases for Acute Leukemia

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 865)
# Related Disease Score Top Affiliating Genes
1 mixed phenotype acute leukemia 33.4 WT1 RUNX1 MTHFR KMT2A GSTM1 FLT3
2 leukemia, acute myeloid 32.8 WT1 TCF3 RUNX1 PBX1 PAX5 KRAS
3 leukemia, acute lymphoblastic 32.6 WT1 TCF3 RUNX1 PBX1 PAX5 MTHFR
4 mixed phenotype acute leukemia with t 32.5 WT1 RUNX1
5 childhood leukemia 32.4 TCF3 RUNX1 PBX1 MTHFR KMT2A ETV6
6 acute promyelocytic leukemia 32.4 WT1 RUNX1 KRAS KMT2A FLT3 ETV6
7 leukemia 32.4 WT1 TCF3 STMN1 RUNX1 PBX1 PAX5
8 chronic leukemia 32.3 WT1 KIT JAK2 FLT3
9 myelodysplastic syndrome 32.3 WT1 RUNX1 KRAS KMT2A KIT JAK2
10 severe congenital neutropenia 32.2 RUNX1 JAK2 FLT3 CSF3
11 myeloproliferative neoplasm 32.2 WT1 RUNX1 KMT2A KIT JAK2 FLT3
12 lymphoblastic lymphoma 32.2 PAX5 KMT2A DNTT
13 myelodysplastic/myeloproliferative neoplasm 32.2 KMT2A KIT JAK2 FLT3 ETV6
14 precursor t-cell acute lymphoblastic leukemia 31.9 KMT2A FLT3 ETV6 DNTT
15 myeloid leukemia 31.9 WT1 RUNX1 KRAS KMT2A KIT JAK2
16 b-lymphoblastic leukemia/lymphoma 31.7 TCF3 PBX1 PAX5 KMT2A KIT FLT3
17 aplastic anemia 31.6 WT1 RUNX1 GSTM1 FLT3 CSF3
18 monocytic leukemia 31.6 RUNX1 KMT2A FLT3
19 pancytopenia 31.6 RUNX1 KMT2A KIT CSF3
20 refractory anemia 31.5 RUNX1 JAK2 CSF3
21 t-cell acute lymphoblastic leukemia 31.5 RUNX1 FLT3 ETV6 DNTT
22 leukemia, chronic myeloid 31.4 WT1 RUNX1 KRAS KMT2A KIT JAK2
23 myeloma, multiple 31.4 TCF3 KRAS KIT JAK2 FLT3 CSF3
24 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 31.4 RUNX1 KMT2A KIT FLT3 ETV6 DNTT
25 thrombocytopenia 31.3 RUNX1 PAX5 MTHFR KRAS KIT JAK2
26 leukemia, acute monocytic 31.3 KMT2A FLT3 CREBBP
27 myelofibrosis 31.3 WT1 RUNX1 KIT JAK2 FLT3 ETV6
28 acute myeloblastic leukemia with maturation 31.3 KIT FLT3
29 polycythemia vera 31.3 KIT JAK2 ETV6 CSF3
30 myeloid sarcoma 31.2 PAX5 KMT2A KIT FLT3 DNTT
31 deficiency anemia 31.2 KIT JAK2 GSTM1 FLT3 CSF3
32 acute megakaryocytic leukemia 31.2 RUNX1 KMT2A KIT JAK2 FLT3 ETV6
33 childhood acute lymphocytic leukemia 31.2 TCF3 RUNX1 PBX1 PAX5 MTHFR KRAS
34 lymphoma, non-hodgkin, familial 31.2 PAX5 KMT2A JAK2 FLT3 ETV6 DNTT
35 down syndrome 31.2 RUNX1 MTHFR JAK2 ETV6
36 adult acute lymphocytic leukemia 31.1 TCF3 PBX1 PAX5 MTHFR ETV6 CSF3
37 childhood acute myeloid leukemia 31.1 WT1 KIT FLT3 BAALC
38 essential thrombocythemia 31.1 MTHFR KRAS KIT JAK2 CSF3
39 leukemia, chronic lymphocytic 31.1 PAX5 KRAS KMT2A JAK2 FLT3 DNTT
40 exanthem 31.1 KRAS KIT CSF3
41 chronic myelomonocytic leukemia 31.0 RUNX1 KRAS KMT2A KIT JAK2 FLT3
42 central nervous system leukemia 31.0 KMT2A AFF1
43 wilms tumor 1 31.0 WT1 KRAS KMT2A FLT3 CREBBP CEBPA
44 hematologic cancer 30.8 WT1 RUNX1 PAX5 KMT2A KIT JAK2
45 mastocytosis 30.7 KIT JAK2 FLT3
46 cytogenetically normal acute myeloid leukemia 30.6 WT1 KMT2A FLT3 CEBPA
47 ewing sarcoma 30.5 WT1 KRAS KIT DNTT CSF3
48 medulloblastoma 30.5 STMN1 PAX5 KIT JAK2 CSF3 CREBBP
49 tetrasomy 21 30.5 RUNX1 DNTT
50 chronic eosinophilic leukemia 30.5 WT1 KIT JAK2 FLT3 ETV6

Comorbidity relations with Acute Leukemia via Phenotypic Disease Network (PDN):


Deficiency Anemia Neutropenia

Graphical network of the top 20 diseases related to Acute Leukemia:



Diseases related to Acute Leukemia

Symptoms & Phenotypes for Acute Leukemia

GenomeRNAi Phenotypes related to Acute Leukemia according to GeneCards Suite gene sharing:

26 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.43 DNTT FLT3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.43 KRAS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.43 KRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 10.43 FLT3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 10.43 CEBPA FLT3
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 10.43 CEBPA FLT3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 10.43 FLT3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.43 CEBPA FLT3 KRAS
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.43 CEBPA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.43 FLT3
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.43 KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.43 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 10.43 FLT3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.43 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.43 FLT3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.43 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-196 10.43 KRAS
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-197 10.43 DNTT
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.43 CEBPA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.43 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 10.43 KRAS WT1
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.43 KRAS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.43 KRAS
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-35 10.43 WT1
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.43 CEBPA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.43 KRAS
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.43 KRAS
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.43 KRAS
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.43 KRAS
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 10.43 CEBPA
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 10.43 KRAS
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 10.43 DNTT
33 Decreased viability GR00055-A-1 10.12 KRAS
34 Decreased viability GR00055-A-2 10.12 KRAS
35 Decreased viability GR00055-A-3 10.12 KRAS
36 Decreased viability GR00106-A-0 10.12 KRAS PAX5
37 Decreased viability GR00173-A 10.12 FLT3
38 Decreased viability GR00221-A-1 10.12 FLT3 KIT KRAS
39 Decreased viability GR00221-A-2 10.12 JAK2 KRAS
40 Decreased viability GR00221-A-4 10.12 FLT3
41 Decreased viability GR00249-S 10.12 GSTM1 PBX1 RUNX1
42 Decreased viability GR00301-A 10.12 KIT KRAS
43 Decreased viability GR00381-A-1 10.12 AFF1 GSTM1 KRAS WT1
44 Decreased viability GR00386-A-1 10.12 CEBPA CREBBP CSF3 GSTM1 MTHFR PAX5
45 Decreased viability GR00402-S-2 10.12 KMT2A RUNX1
46 Reduced mammosphere formation GR00396-S 9.23 CEBPA CSF3 ETV6 GSTM1 KMT2A KRAS

MGI Mouse Phenotypes related to Acute Leukemia:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.47 AFF1 CEBPA CREBBP DNTT ETV6 FLT3
2 hematopoietic system MP:0005397 10.46 AFF1 CEBPA CREBBP CSF3 DNTT ETV6
3 homeostasis/metabolism MP:0005376 10.45 CEBPA CREBBP DNTT ETV6 FLT3 JAK2
4 immune system MP:0005387 10.44 AFF1 CEBPA CREBBP CSF3 DNTT ETV6
5 cellular MP:0005384 10.4 CEBPA CREBBP ETV6 FLT3 JAK2 KIT
6 cardiovascular system MP:0005385 10.38 CEBPA CREBBP ETV6 JAK2 KIT KMT2A
7 endocrine/exocrine gland MP:0005379 10.35 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
8 mortality/aging MP:0010768 10.35 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
9 embryo MP:0005380 10.28 CREBBP ETV6 JAK2 KIT KMT2A KRAS
10 liver/biliary system MP:0005370 10.27 CEBPA CREBBP ETV6 JAK2 KIT KMT2A
11 integument MP:0010771 10.26 CEBPA CREBBP CSF3 ETV6 JAK2 KIT
12 neoplasm MP:0002006 10.21 CEBPA CREBBP ETV6 FLT3 JAK2 KIT
13 normal MP:0002873 10.17 CEBPA CREBBP DNTT ETV6 JAK2 KIT
14 nervous system MP:0003631 10.14 AFF1 CREBBP KIT KMT2A KRAS MTHFR
15 muscle MP:0005369 10.11 CEBPA CREBBP KIT KMT2A KRAS PAX5
16 no phenotypic analysis MP:0003012 10.11 AFF1 CEBPA ETV6 FLT3 KIT KMT2A
17 limbs/digits/tail MP:0005371 10.05 CREBBP KIT KMT2A KRAS MTHFR PBX1
18 renal/urinary system MP:0005367 9.86 CEBPA CSF3 KIT KMT2A KRAS PBX1
19 reproductive system MP:0005389 9.85 AFF1 CEBPA JAK2 KIT KMT2A KRAS
20 respiratory system MP:0005388 9.56 CEBPA CREBBP JAK2 KIT KRAS PBX1
21 skeleton MP:0005390 9.36 CREBBP DNTT FLT3 JAK2 KIT KMT2A

Drugs & Therapeutics for Acute Leukemia

Drugs for Acute Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
2
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
3
Rasburicase Approved, Investigational Phase 4 134774-45-1
4
Uric acid Investigational Phase 4 69-93-2 1175
5 Pharmaceutical Solutions Phase 4
6
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
Oprelvekin Approved, Investigational Phase 2, Phase 3 145941-26-0
9
Dalteparin Approved Phase 3 9005-49-6
10
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
11
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
12
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
13
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
14
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
15
Ofloxacin Approved Phase 3 82419-36-1 4583
16
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
17
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Clove Approved Phase 2, Phase 3 84961-50-2
20
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668
21
Thioguanine Approved Phase 3 154-42-7 2723601
22
Pegaspargase Approved, Investigational Phase 3 130167-69-0
23
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
24
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
25
Venetoclax Approved, Investigational Phase 3 1257044-40-8 49846579
26
Ichthammol Approved Phase 3 8029-68-3
27
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
28
tannic acid Approved Phase 3 1401-55-4
29
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
30
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
31
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
32
Abatacept Approved Phase 3 332348-12-6 10237
33
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
34
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
35
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
36
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
37
Sodium citrate Approved, Investigational Phase 3 68-04-2
38
rituximab Approved Phase 3 174722-31-7 10201696
39
Mesna Approved, Investigational Phase 3 3375-50-6 598
40
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
41
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
42 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
43
Cortisone Experimental Phase 3 53-06-5 222786
44
Semustine Experimental, Investigational Phase 2, Phase 3 13909-09-6
45 Anesthetics, Dissociative Phase 3
46 Antiparasitic Agents Phase 3
47 Antiprotozoal Agents Phase 3
48 Cola Phase 3
49 Heparin, Low-Molecular-Weight Phase 3
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 417)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Unknown status NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
2 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
3 Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil Completed NCT04187755 Phase 4 Ceftazidime Injection;Cefepime Injection
4 An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin¿s Lymphoma and Acute Leukemia Active, not recruiting NCT04349306 Phase 4 RASBURICASE SR29142
5 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
6 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
7 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
9 Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial. Unknown status NCT00624143 Phase 3 ORAL VORICONAZOLE and IV Amphotericin B
10 TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia Unknown status NCT00914628 Phase 3
11 Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia in Patients With Acute Leukemia Receiving Chemotherapy Unknown status NCT02241031 Phase 2, Phase 3 thrombopoietin (TPO) and interleukin-11
12 A Prospective, Multicenter Randomized Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in Children and Young Adults (<35 Years) With Acute Leukemia Remission Unknown status NCT01067300 Phase 3
13 Randomized Multicenter Trial of Two Transfusion Strategies for Patient Receiving Chemotherapy for Acute Leukemia or Hematopoietic Stem Cells With Medico-economic Evaluation of Cost Minimization. Unknown status NCT02461264 Phase 3 Single red blood packed cells Transfusion;Two packed red blood cells Transfusion
14 A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
15 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
16 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
17 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
18 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
19 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
20 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
21 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
22 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
23 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
24 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
25 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
26 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
27 A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT01371656 Phase 3 levofloxacin
28 Clofarabine, Cyclophosfamide, And Etoposide For The Treatment Of Relapsed Or Resistant Acute Leukemia In Pediatric Patients Completed NCT01385891 Phase 2, Phase 3 Clofarabine VP 16 ciclophospahamide
29 A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT01020175 Phase 3
30 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
31 Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3 Negative Acute Leukemia Recruiting NCT04674345 Phase 2, Phase 3 Sorafenib
32 Hypomethylating Agents + Donor Lymphocyte Infusion vs Donor Lymphocyte Infusion Preemptive Therapy Based on Minimal Residual Disease for Acute Leukemia Undergoing Allogenetic Hematopoietic Stem Cell Transplantation Recruiting NCT03662087 Phase 2, Phase 3
33 A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN #1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN #1801; Mi-Immune) Recruiting NCT03959241 Phase 3 Tacrolimus;Methotrexate;Tacrolimus;Mycophenolate Mofetil;Cyclophosphamide
34 Phase III Randomized Clinical Trial Comparing Post-Transplant Cyclophosphamide With Calcineurin Inhibitors as GVHD Prophylaxis to Standard Care of Methotrexate and Calcineurin Inhibitors for Acute Leukemia Incorporating Patient Pharmacogenomics Profiling (PMAT) Recruiting NCT04314219 Phase 3 Cyclophosphamide 50mg;Methotrexate
35 Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03596892 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY)
36 Decitabine Plus mBU/CY for High Risk Acute Leukemia With Minimal Residual Disease Pre-HSCT Recruiting NCT03793517 Phase 2, Phase 3 Decitabine;mBU/CY and ATG;mBU/CY
37 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy Recruiting NCT03959085 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
38 Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Patients Undergoing HSCT Recruiting NCT03799224 Phase 2, Phase 3 Decitabine;mBU/CY and ATG;mBU/CY
39 A Phase III, Randomized, Clinical Trial Comparing Two Diets in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) or Remission Induction Chemotherapy for Acute Leukemia and Myelodysplastic Syndrome (UF-BMT-LDND-101) Recruiting NCT03016130 Phase 3
40 A Phase I-II Pilot Clinical Trial of Safety and Efficacy of Personalized Targeted Preparative Regimen With Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation and Posttransplant Donor T- Cells Infusion in Children With Chemoresistаnt Acute Leukemia. Recruiting NCT04000698 Phase 3 Preparative regimen
41 Extension of a Phase III Randomized Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen-HaploMUD-RIC-01 Active, not recruiting NCT03595800 Phase 3
42 A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II) Active, not recruiting NCT02345850 Phase 3 Cyclophosphamide;Tacrolimus;Methotrexate
43 Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial Active, not recruiting NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
44 Allogeneic Stem Cell Transplantation Using Mylotarg (CMA-676) Plus Nonmyeloablative Chemotherapy in Older or Medically Infirm Patients With High-Risk Acute Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS) Terminated NCT00038805 Phase 2, Phase 3 Mylotarg
45 T-cell Depletion In Unrelated Donor Marrow Transplantation Withdrawn NCT00006451 Phase 3 anti-thymocyte globulin;cyclophosphamide;cyclosporine;methotrexate;methylprednisolone
46 Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia Withdrawn NCT00943709 Phase 3 therapeutic insulin
47 Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies Unknown status NCT01385072 Phase 1, Phase 2
48 Phase 2 Double-blind, Randomized, Placebo Controlled Clinical Trial for the Prevention of Oral Mucositis Using Sub-microbial Doses of Doxycycline Hyclate in Patients With Acute Leukemia Receiving Induction Chemotherapy Unknown status NCT01087476 Phase 2 Doxycycline hyclate
49 Interferon α After Prophylactic Donor Lymphocyte Infusion for the Relapse Prevention After Hematopoietic Stem Cell Transplantation Unknown status NCT02568241 Phase 1, Phase 2
50 Haploidentical Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells in Pediatric Patients With Refractory Hematological and Oncological Diseases Unknown status NCT01919866 Phase 1, Phase 2

Search NIH Clinical Center for Acute Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Acute Leukemia:
Promostem, mesenchymal stem cells for treatment of graft-versus-host disease

Genetic Tests for Acute Leukemia

Genetic tests related to Acute Leukemia:

# Genetic test Affiliating Genes
1 Acute Leukemia 29

Anatomical Context for Acute Leukemia

MalaCards organs/tissues related to Acute Leukemia:

40
Bone, Myeloid, Bone Marrow, T Cells, Breast, Liver, Skin

Publications for Acute Leukemia

Articles related to Acute Leukemia:

(show top 50) (show all 17560)
# Title Authors PMID Year
1
Bench to bedside targeting of FLT3 in acute leukemia. 54 61
20370649 2010
2
A role for PKR in hematologic malignancies. 54 61
20232306 2010
3
Targeting CREB for cancer therapy: friend or foe. 54 61
20370681 2010
4
Clinical correlation of circulating heat shock protein 70 in acute leukemia. 61 54
19800118 2010
5
Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature. 54 61
20206559 2010
6
RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. 54 61
20181616 2010
7
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. 54 61
20072157 2010
8
The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. 61 54
20111912 2010
9
[Expression of CREB/Bcl-2 in bone marrow mononuclear cells of children with acute leukemia]. 54 61
20350424 2010
10
Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. 54 61
20007546 2010
11
Droplet-based gene expression analysis using a device with magnetic force-based-droplet-handling system. 54 61
20129107 2010
12
Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. 54 61
19935430 2010
13
Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. 61 54
20306249 2010
14
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. 54 61
20145726 2010
15
[FLT3 gene mutation and its prognostic implication in patients with acute leukemia.]. 54 61
20302766 2010
16
[Clinical significance of detecting serum erythropoietin in patients with leukemia]. 61 54
19923094 2009
17
PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. 54 61
19507191 2009
18
Discrepant immunophenotypic characteristics between the lymph node and bone marrow in two mixed-phenotype acute leukemia patients. 54 61
19893347 2009
19
Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients. 61 54
19848320 2009
20
Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. 61 54
19530238 2009
21
New insights to the MLL recombinome of acute leukemias. 61 54
19262598 2009
22
ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. 61 54
19635183 2009
23
[Studies on the mutation and polymorphism of the TPMT gene in Chinese children with acute leukemia]. 54 61
20017316 2009
24
Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. 61 54
19811333 2009
25
GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. 61 54
19212333 2009
26
Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. 61 54
19454497 2009
27
Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. 54 61
19411632 2009
28
Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. 54 61
19250671 2009
29
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. 61 54
19357396 2009
30
Detection of myeloperoxidase activity in primary leukemic cells by an enhanced chemiluminescent assay for differentiation between acute lymphoblastic and non-lymphoblastic leukemia. 61 54
19298796 2009
31
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. 61 54
19279403 2009
32
[Myeloproliferative diseases caused by JAK2 mutation]. 61 54
19489438 2009
33
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia]. 61 54
19379589 2009
34
Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. 54 61
19151769 2009
35
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. 61 54
19036706 2009
36
Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. 61 54
19202074 2009
37
Acute leukemia of ambiguous lineage, biphenotype, without CD34, TdT or TCR-rearrangement. 54 61
19687594 2009
38
The role of myeloid growth factors in acute leukemia. 54 61
19176208 2009
39
RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. 61 54
18977066 2009
40
A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. 54 61
18948576 2009
41
Maternal acute lymphoctic leukemia with rearrangement of the mixed lineage leukemia gene occurring during pregnancy. 54 61
20139053 2009
42
Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow. 61 54
19327122 2009
43
New thrombopoietic growth factors. 54 61
19778863 2009
44
Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects. 54 61
19074864 2008
45
[Expression of erythropoietin receptor in leukemia cells and relation of erythropoietin level with leukemic anemia]. 61 54
19099624 2008
46
[Expression of SALL4 and BMI-1 mRNA in acute leukemia]. 61 54
19099625 2008
47
Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia. 54 61
19052976 2008
48
Assessment of P-gp and MRP1 activities using MultiDrugQuant Assay Kit: a preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients. 61 54
19291917 2008
49
[Expression of cyclin A in childhood acute leukemia and its significance]. 54 61
19176011 2008
50
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. 61 54
18948750 2008

Variations for Acute Leukemia

Expression for Acute Leukemia

Search GEO for disease gene expression data for Acute Leukemia.

Pathways for Acute Leukemia

GO Terms for Acute Leukemia

Cellular components related to Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10.06 WT1 TCF3 RUNX1 PBX1 PAX5 KMT2A
2 transcription factor complex GO:0005667 9.56 TCF3 PBX1 CREBBP CEBPA
3 RNA polymerase II transcription factor complex GO:0090575 9.33 TCF3 PBX1 CEBPA
4 chromatin GO:0000785 9.23 WT1 TCF3 RUNX1 PBX1 PAX5 ETV6
5 euchromatin GO:0000791 9.13 TCF3 JAK2 DNTT

Biological processes related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.14 WT1 TCF3 RUNX1 PBX1 PAX5 KIT
2 multicellular organism development GO:0007275 10.07 STMN1 PBX1 PAX5 KIT FLT3 CSF3
3 cell differentiation GO:0030154 10 TCF3 STMN1 PBX1 PAX5 JAK2 FLT3
4 positive regulation of transcription, DNA-templated GO:0045893 9.97 WT1 TCF3 RUNX1 KMT2A CREBBP CEBPA
5 negative regulation of transcription by RNA polymerase II GO:0000122 9.95 WT1 TCF3 RUNX1 PAX5 ETV6 CREBBP
6 MAPK cascade GO:0000165 9.91 KRAS KIT JAK2 FLT3
7 positive regulation of cell proliferation GO:0008284 9.91 PBX1 KRAS KIT JAK2 FLT3 CSF3
8 regulation of transcription, DNA-templated GO:0006355 9.91 WT1 TCF3 RUNX1 PBX1 PAX5 KMT2A
9 B cell differentiation GO:0030183 9.75 TCF3 KIT FLT3
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 KIT JAK2 FLT3
11 regulation of hematopoietic stem cell differentiation GO:1902036 9.73 TCF3 RUNX1 KMT2A
12 hemopoiesis GO:0030097 9.72 RUNX1 KIT FLT3
13 positive regulation of MAP kinase activity GO:0043406 9.69 KRAS KIT FLT3
14 positive regulation of DNA-binding transcription factor activity GO:0051091 9.67 TCF3 KIT JAK2 CSF3
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.62 KIT JAK2 FLT3 CSF3
16 hematopoietic stem cell proliferation GO:0071425 9.61 RUNX1 ETV6
17 regulation of myeloid cell differentiation GO:0045637 9.6 RUNX1 CREBBP
18 regulation of B cell receptor signaling pathway GO:0050855 9.59 RUNX1 PAX5
19 granulocyte differentiation GO:0030851 9.58 CSF3 CEBPA
20 myeloid progenitor cell differentiation GO:0002318 9.48 KIT FLT3
21 cytokine-mediated signaling pathway GO:0019221 9.43 KRAS KIT JAK2 FLT3 CSF3 CEBPA
22 embryonic hemopoiesis GO:0035162 9.33 PBX1 KMT2A KIT
23 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 WT1 TCF3 RUNX1 PBX1 PAX5 KMT2A

Molecular functions related to Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.45 WT1 TCF3 STMN1 RUNX1 PBX1 PAX5
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.98 WT1 TCF3 RUNX1 PBX1 PAX5 ETV6
3 DNA binding GO:0003677 9.97 WT1 TCF3 RUNX1 PBX1 PAX5 KMT2A
4 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.91 WT1 TCF3 RUNX1 PBX1 PAX5 ETV6
5 sequence-specific DNA binding GO:0043565 9.8 WT1 TCF3 PBX1 ETV6 CEBPA
6 transcription regulatory region sequence-specific DNA binding GO:0000976 9.76 WT1 TCF3 RUNX1 CEBPA
7 protein homodimerization activity GO:0042803 9.73 TCF3 RUNX1 KMT2A KIT GSTM1 CEBPA
8 transcription factor binding GO:0008134 9.55 TCF3 RUNX1 PBX1 CREBBP CEBPA
9 DNA-binding transcription factor activity GO:0003700 9.5 WT1 TCF3 RUNX1 PBX1 PAX5 ETV6
10 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.17 WT1 TCF3 RUNX1 PBX1 PAX5 ETV6

Sources for Acute Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....